Healthcare
Infographic: Which Rare Diseases Are The Most Common?
Infographic: Which Rare Diseases Are The Most Common?
Pharmaceuticals have come a long way since the apothecary days of prescribing cocaine drops for toothaches, or dispensing tapeworm diet pills.
Today, medical breakthroughs like antibiotics and vaccines save millions of lives, and contribute to the industry’s mammoth size. Yet even with rapid advancements, a select group of rare diseases still fly under the radar — and together, they affect over 350 million people worldwide.
What Are Rare Diseases?
Today’s infographic from Raconteur breaks down occurrence rates of notable rare diseases, and their collective impact on pharmaceutical drug sales. But first, let’s look at how they’re defined.
Diseases are considered rare, or “orphan” if they affect only a small proportion of the population. In general, it’s estimated that 1 in 17 people will be afflicted by a rare disease in their lifetime. At the same time, as many as 7,000 rare diseases exist, with more discovered every year.
A report by the global investment bank Torreya looks at the most common types of rare diseases that are a focus for therapeutic companies around the world:
- Multiple sclerosis emerges above all others, at 90 patients per 100,000 people.
- Narcolepsy—intermittent, uncontrollable episodes of sleepiness—affects 50 patients per 100,000.
- Primary biliary cholangitis, the damage of bile ducts in the liver, affects 40 people in 100,000.
- Rounding out the top five orphan diseases are Fabry disease (30 patients per 100,000), and cystic fibrosis (25 patients per 100,000).
One catch behind these stats? There’s actually no universal definition of what constitutes a rare disease. This means prevalence data like the above is often inconsistent, making it difficult to record the precise rate of natural occurrence.
The Cost of Rare Diseases
This gap in knowledge comes at a price—many rare diseases have constrained options for treatment. Orphan drugs are often commercially underdeveloped, as their limited end-market usage means they aren’t usually profitable enough for traditional research.
In the United States, government-backed incentives such as tax credits for R&D costs and clinical trials are speeding up the pathways from drug to market. Other places like the EU, Japan, and Australia are also following suit.
In total, it’s estimated that pharma companies focused on rare diseases are worth about half a trillion in enterprise value, roughly equal to 17.5% of the value of Big Pharma:
- Non-oncology value: $315.7B
- Oncology value: $193.1B
- Total enterprise value: $508.8B
Source: Torreya Report. Market values are for the top 31 pure play rare disease therapeutic companies.
The average cost of an orphan drug per U.S. patient annually can climb to near $151,000 (a whopping 4.5 times that of a non-orphan drug, at $34,000). That’s why the pharma industry is urgently advancing rare disease therapeutics across different categories.
Dominant Orphan Drug Sales
According to other estimates, orphan drugs are set to capture over one-fifth of global prescription sales by 2024. Blood, central nervous system, and respiratory-related drugs are currently the top therapeutic categories and are expected to keep this status into the future.
The figures below break down global orphan drug sales by therapy category, and their present and estimated future market share. Note that oncology-related orphan drug sales are excluded from this table.
Therapy Category | 2018 Sales | Market Share | 2024E Sales | Market Share | Change in Market Share |
---|---|---|---|---|---|
Blood | $21.3B | 31.4% | $33.1B | 27.9% | -3.4% |
Central nervous system (CNS) | $11.1B | 16.3% | $20.3B | 17.1% | 0.8% |
Respiratory | $7.8B | 11.5% | $13.6B | 11.5% | 0% |
Immunomodulators | $7B | 10.3% | $12.5B | 10.5% | 0.2% |
Cardiovascular | $6.7B | 9.9% | $8.5B | 7.2% | -2.7% |
Endocrine | $3.8B | 5.6% | $5.6B | 4.7% | -0.9% |
Musculoskeletal | $3.5B | 5.2% | $11B | 9.3% | 4.1% |
Systemic anti-infectives | $3.1B | 4.6% | $4.2B | 3.5% | -1% |
Gastro-intestinal | $2.9B | 4.3% | $6B | 5.1% | 0.8% |
Genito-urinary | $0.6B | 0.9% | $1.5B | 1.3% | 0.4% |
Sensory organs | $0.1B | 0.1% | $1.5B | 1.3% | 1.1% |
Dermatology | $0B | 0% | $0.7B | 0.6% | 0.6% |
Total Sales | $67.9B | $118.5B |
Source: EvaluatePharma. Industry sales are based on the top 500 pharma and biotech companies.
Much is still unknown about rare diseases in the health community. Frequent misdiagnosis, and up to an average of 8 years for an accurate diagnosis, continue to be a problem for patients.
There are two sides to the situation. On one, tech giants like Microsoft are providing digital health solutions to speed up diagnosis, through machine learning and blockchain-based patient registry.
On the other, many skeptics question whether the industry is interested in finding cures for rare diseases at all, especially when they account for a significant portion of industry revenues.
Is curing patients a sustainable business model?
Politics
Timeline: Cannabis Legislation in the U.S.
At the federal level, cannabis is illegal, but state laws differ. This graphic looks at the timelines of cannabis legislation in the U.S.

Timeline: Cannabis Legislation in the U.S.
At the federal level, cannabis is still considered an illegal substance. That said, individual states do have the right to determine their own laws around cannabis sales and usage.
This visual from New Frontier Data looks at the status of cannabis in every state and the timeline of when medical and/or recreational use became legal.
Cannabis Through the Years
In the U.S., the oldest legalese concerning cannabis dates back to the 1600s—the colony of Virginia required every farm to grow and produce hemp. Since then, cannabis use was fairly wide open until the 1930s when the Marihuana Tax Act was enforced, prohibiting marijuana federally but still technically allowing medical use.
Jumping ahead, the Controlled Substances Act was passed in 1970, classifying cannabis as Schedule I drug—the same category as heroin. This prohibited any use of the substance.
However, the 1970s also saw a counter movement, wherein many states made the move towards decriminalization. Decriminalization means that although possessing cannabis remained illegal, a person would not be subject to jail time or prosecution for possessing certain amounts.
By the 1990s, some of the first states passed laws to allow the medical usage of cannabis, and by 2012 two states in the U.S.—Washington and Colorado—legalized the recreational use of cannabis.
Cannabis Legislation Today and Beyond
The MORE Act (the Marijuana Opportunity Reinvestment and Expungement Act) was passed in the House early 2022, and if made law, it would decriminalize marijuana federally.
“This bill decriminalizes marijuana. Specifically, it removes marijuana from the list of scheduled substances under the Controlled Substances Act and eliminates criminal penalties for an individual who manufactures, distributes, or possesses marijuana.”– U.S. Congress
Cannabis still remains illegal at the federal level, but at the state levels, cannabis is now fully legal (both for medicinal and recreational purposes) in a total of 22 states.
Over 246 million Americans have legal access to some form of marijuana products with high THC levels. Looking to the future, many new cannabis markets are expected to open up in the next few years:
The earliest states expected to open up next for recreational cannabis sales are Minnesota and Oklahoma. There is always a lag between legalization and actual sales, wherein local regulatory bodies and governments set standards. States like Kentucky, on the other hand, aren’t likely to even legalize medicinal cannabis until 2028.
It’s estimated that by 2030, there will be 69 million cannabis consumers in the country, up 33% from 2022.
Overall, the U.S. cannabis market is likely an important one to watch as legal sales hit $30 billion in 2022. By the end of the decade, that number is expected to be anywhere from $58 billion to as much as $72 billion.
-
Datastream2 weeks ago
Mapped: Legal Sports Betting Totals by State
-
Politics1 day ago
Timeline: Cannabis Legislation in the U.S.
-
Energy4 weeks ago
Which Countries are Buying Russian Fossil Fuels?
-
Datastream2 weeks ago
The Largest U.S. Bank Failures in Modern History
-
United States3 weeks ago
Visualized: The State of the U.S. Labor Market
-
Debt2 weeks ago
The Growing Auto Loan Problem Facing Young Americans
-
Economy3 weeks ago
Ranked: Who Are the Richest People in Africa?
-
Datastream2 weeks ago
Network Overload? Adding Up the Data Produced By Connected Cars